ChromaDex (CDXC) Competitors $7.71 +0.15 (+1.98%) (As of 11:39 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CDXC vs. CNTA, KROS, AKRO, MIRM, AMPH, JANX, APGE, RXRX, HRMY, and IRONShould you be buying ChromaDex stock or one of its competitors? The main competitors of ChromaDex include Centessa Pharmaceuticals (CNTA), Keros Therapeutics (KROS), Akero Therapeutics (AKRO), Mirum Pharmaceuticals (MIRM), Amphastar Pharmaceuticals (AMPH), Janux Therapeutics (JANX), Apogee Therapeutics (APGE), Recursion Pharmaceuticals (RXRX), Harmony Biosciences (HRMY), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. ChromaDex vs. Centessa Pharmaceuticals Keros Therapeutics Akero Therapeutics Mirum Pharmaceuticals Amphastar Pharmaceuticals Janux Therapeutics Apogee Therapeutics Recursion Pharmaceuticals Harmony Biosciences Disc Medicine Centessa Pharmaceuticals (NASDAQ:CNTA) and ChromaDex (NASDAQ:CDXC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability. Do insiders and institutionals believe in CNTA or CDXC? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of ChromaDex shares are owned by institutional investors. 11.6% of Centessa Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of ChromaDex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better earnings & valuation, CNTA or CDXC? ChromaDex has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M326.26-$151.09M-$1.53-11.08ChromaDex$83.57M7.05-$4.94M$0.01771.77 Which has more risk and volatility, CNTA or CDXC? Centessa Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, ChromaDex has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Is CNTA or CDXC more profitable? ChromaDex has a net margin of 1.62% compared to Centessa Pharmaceuticals' net margin of 0.00%. ChromaDex's return on equity of 4.85% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -52.13% -38.01% ChromaDex 1.62%4.85%2.70% Do analysts recommend CNTA or CDXC? Centessa Pharmaceuticals currently has a consensus target price of $25.83, suggesting a potential upside of 52.41%. ChromaDex has a consensus target price of $8.00, suggesting a potential upside of 3.76%. Given Centessa Pharmaceuticals' higher possible upside, equities analysts clearly believe Centessa Pharmaceuticals is more favorable than ChromaDex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00ChromaDex 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CNTA or CDXC? ChromaDex received 511 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 64.29% of users gave ChromaDex an outperform vote while only 56.86% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCentessa PharmaceuticalsOutperform Votes2956.86% Underperform Votes2243.14% ChromaDexOutperform Votes54064.29% Underperform Votes30035.71% Does the media refer more to CNTA or CDXC? In the previous week, Centessa Pharmaceuticals had 8 more articles in the media than ChromaDex. MarketBeat recorded 11 mentions for Centessa Pharmaceuticals and 3 mentions for ChromaDex. ChromaDex's average media sentiment score of 1.54 beat Centessa Pharmaceuticals' score of 0.73 indicating that ChromaDex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ChromaDex 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryChromaDex beats Centessa Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Ad Brownstone ResearchMedia Is Mocking Elon, But Wait Until They See This DemoElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get ChromaDex News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXC vs. The Competition Export to ExcelMetricChromaDexMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$588.89M$1.26B$5.20B$8.97BDividend YieldN/AN/A5.23%4.04%P/E Ratio771.7724.3085.7113.39Price / Sales7.057.941,469.4286.49Price / CashN/A11.6335.2935.09Price / Book20.292.214.914.96Net Income-$4.94M-$51.46M$117.36M$224.10M7 Day Performance1.58%0.67%2.75%2.01%1 Month Performance31.57%-5.68%1.71%9.79%1 Year Performance446.81%5.89%36.01%29.97% ChromaDex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXCChromaDex4.2113 of 5 stars$7.71+2.0%$8.00+3.8%+436.2%$588.89M$83.57M771.77106Short Interest ↓Positive NewsCNTACentessa Pharmaceuticals4.0815 of 5 stars$17.44-2.6%$25.83+48.1%+153.0%$2.30B$6.85M-11.5272Short Interest ↑News CoverageKROSKeros Therapeutics3.9458 of 5 stars$56.50-2.1%$88.89+57.3%+85.2%$2.29B$651,000.00-11.08100Short Interest ↓News CoveragePositive NewsAKROAkero Therapeutics4.1709 of 5 stars$32.39+0.9%$46.83+44.6%+81.3%$2.26BN/A-8.5630Positive NewsMIRMMirum Pharmaceuticals3.909 of 5 stars$45.68-1.2%$57.73+26.4%+44.4%$2.19B$307.03M-22.88140Positive NewsAMPHAmphastar Pharmaceuticals4.9158 of 5 stars$45.20+0.0%$60.33+33.5%-20.8%$2.17B$644.40M15.061,761Positive NewsJANXJanux Therapeutics3.9792 of 5 stars$40.65-10.1%$67.70+66.5%+344.5%$2.13B$13.05M-35.2630Analyst ForecastGap UpAPGEApogee Therapeutics2.514 of 5 stars$46.57+3.1%$83.88+80.1%+132.2%$2.10BN/A-19.1491Analyst ForecastRXRXRecursion Pharmaceuticals1.3541 of 5 stars$7.07+10.8%$9.25+30.8%+2.6%$2.03B$64.60M-4.62400High Trading VolumeHRMYHarmony Biosciences4.7969 of 5 stars$35.22+1.6%$47.00+33.4%+15.3%$2.01B$681.88M16.43200Positive NewsIRONDisc Medicine2.9632 of 5 stars$65.45+3.2%$85.80+31.1%+15.2%$1.95BN/A-16.2678 Related Companies and Tools Related Companies CNTA Competitors KROS Competitors AKRO Competitors MIRM Competitors AMPH Competitors JANX Competitors APGE Competitors RXRX Competitors HRMY Competitors IRON Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDXC) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ChromaDex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
